Vertaling van "one where bupropion was evaluated " (Nederlands → Frans) :

The results of these trials are concordant with previous trials, except one where bupropion was evaluated in an unmotivated population.
The results of these trials are concordant with previous trials, except one where Bupropion was evaluated in an unmotivated population.

2000 € Minimal counselling by a GP consists of one or two consultations with a total length of 12 minutes, not provided as part of a consultation for other health reasons Minimal counselling+NRT is provided for a period of 8 weeks Intensive counselling+NRT is provided by a trained lung nurse for a total of 90 minutes after a brief advice from a lung physician, period of NRT is 12 weeks Intensive counselling+bupropion included intensive counselling as described above with bupropion for a period of 9 weeks Telephone counselling consists of one intake call of 30 minutes and six follow-up calls of each 15 minutes Costs of self-help materials was included One defined daily dose (DDD) equals 14 mg for NRT patches.
2000 € Minimal counselling by a GP consists of one or two consultations with a total length of 12 minutes, not provided as part of a consultation for other health reasons Minimal counselling+NRT is provided for a period of 8 weeks Intensive counselling+NRT is provided by a trained lung nurse for a total of 90 minutes after a brief advice from a lung physician, period of NRT is 12 weeks Intensive counselling+Buproprion included intensive counselling as described above with Buproprion for a period of 9 weeks Telephone counselling consists of one intake call of 30 minutes and six follow-up calls of each 15 minutes Costs of self-help materials was included One defined daily dose (DDD) equals 14 mg for NRT patches.

Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR bupropion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.
Spontaneous cessation rate: 2.5% OR counselling only: 1.73 Incremental OR NRT gum (relative to counselling only): 1.63 Incremental OR NRT patch (relative to counselling only): 1.79 Incremental OR NRT spray (relative to counselling only): 2.35 Incremental OR NRT inhaler (relative to counselling only): 2.14 Incremental OR Buproprion (relative to counselling only): 2.30 % of smokers still under treatment after the first month: 50% (range 40-60% in sensitivity analysis) % of smokers still under treatment after the second month: 20% (range 15-25% in sensitivity analysis) Lifetime relapse probability after one year of abstinence: 35% (range 10-50% in sensitivity analysis) Effect of smoking cessation on mortality derived from the results of the American Cancer Society Prevention Study II. The mortality rate for former smokers was projected by calculating a weighted average of the incremental differentials between mortality rates of neversmokers and smokers, weighted according to the duration of abstinence.

Results of a one-year study, which was undertaken in response to “approvable letters” from the FDA, achieved primary efficacy and renal function targets and were also consistent with experience seen in 70 countries – including in Europe – where this medicine has been approved.
Les résultats d’une étude d’un an, entreprise en réponse à des «approvable letters» émises par la FDA, a atteints ses objectifs principaux en termes d’efficacité et de fonction rénale. Ces résultats étaient également en adéquation avec les expériences récoltées dans 70 pays – notamment en Europe – où ce médicament est autorisé.